Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ANNX

Annexon Inc

Last Close
Dec 01 • 04:00PM ET
2.34
Dollar change
-0.15
Percentage change
-6.02 		%
IndexRUT P/E- EPS (ttm)-1.90 Insider Own27.39% Shs Outstand47.72M Perf Week-13.97%
Market Cap124.58M Forward P/E- EPS next Y-1.83 Insider Trans0.00% Shs Float38.66M Perf Month-2.50%
Income-140.73M PEG- EPS next Q-0.48 Inst Own73.88% Short Float / Ratio5.55% / 5.84 Perf Quarter-19.59%
Sales0.00M P/S- EPS this Y26.74% Inst Trans16.56% Short Interest2.15M Perf Half Y-21.48%
Book/sh2.95 P/B0.79 EPS next Y3.74% ROA-54.49% Target Price9.00 Perf Year-56.99%
Cash/sh3.10 P/C0.75 EPS next 5Y38.60% ROE-67.42% 52W Range1.57 - 7.65 Perf YTD-54.74%
Dividend- P/FCF- EPS past 5Y-39.49% ROI-75.40% 52W High-69.41% Beta0.74
Dividend %- Quick Ratio9.85 Sales past 5Y0.00% Gross Margin- 52W Low49.04% ATR0.22
Employees80 Current Ratio9.85 Sales Q/Q- Oper. Margin0.00% RSI (14)47.70 Volatility9.16% 9.54%
OptionableYes Debt/Eq0.20 EPS Q/Q15.57% Profit Margin- Rel Volume1.08 Prev Close2.49
ShortableYes LT Debt/Eq0.19 EarningsNov 13 BMO Payout- Avg Volume367.20K Price2.34
Recom1.44 SMA20-4.27% SMA506.00% SMA200-33.54% Volume397,517 Change-6.02%
Date Action Analyst Rating Change Price Target Change
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Aug-18-20Initiated JP Morgan Overweight $33
Aug-18-20Initiated Cowen Outperform
Show Previous Ratings
Nov-22-23 04:01PM
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
(GlobeNewswire)
Nov-14-23 07:20PM
Annexon Inc (ANNX) Reports Q3 2023 Financial Results and Clinical Progress
(GuruFocus.com) +9.73%
Nov-13-23 06:30AM
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
(GlobeNewswire) +6.35%
Nov-09-23 06:30AM
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference
(GlobeNewswire)
Oct-24-23 06:30AM
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
(GlobeNewswire) +8.33%
04:01PM Loading…
Oct-18-23 04:01PM
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-10-23 06:30AM
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
(GlobeNewswire)
06:30AM
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barr Syndrome (GBS)
(GlobeNewswire)
Sep-19-23 06:30AM
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
(GlobeNewswire)
Sep-18-23 04:01PM
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-08-23 09:35AM
Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)
(Zacks)
Aug-07-23 06:30AM
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
(GlobeNewswire)
Aug-02-23 04:01PM
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jul-30-23 12:00PM
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
(GlobeNewswire)
Jul-27-23 06:30AM
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
(GlobeNewswire) -6.82%
06:30AM Loading…
Jul-24-23 06:30AM
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
(GlobeNewswire)
Jun-14-23 08:36AM
Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
(Simply Wall St.) -5.48%
May-30-23 10:40AM
Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
(Zacks)
May-26-23 03:05AM
4 big analyst cuts: Snowflake downgraded twice on guidance miss
(Investing.com) +35.71%
May-25-23 11:52AM
Why Shares of Annexon Are Plummeting Thursday
(Motley Fool) -59.38%
10:12AM
Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study
(Benzinga)
May-24-23 04:01PM
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
(GlobeNewswire) -7.84%
May-16-23 04:01PM
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
May-08-23 04:01PM
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
(GlobeNewswire)
Apr-11-23 06:30AM
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
(GlobeNewswire) +5.95%
Mar-25-23 08:04AM
One Annexon, Inc. (NASDAQ:ANNX) insider upped their stake by 59% in the previous year
(Simply Wall St.)
Mar-06-23 06:30AM
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
(GlobeNewswire) -6.77%
Feb-27-23 06:30AM
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
(GlobeNewswire)
Feb-16-23 04:05PM
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-12-23 07:35AM
Annexon, Inc.'s (NASDAQ:ANNX) Intrinsic Value Is Potentially 27% Above Its Share Price
(Simply Wall St.)
04:30PM Loading…
Jan-17-23 04:30PM
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-08-23 09:00AM
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
(GlobeNewswire)
Jan-06-23 06:30AM
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
(GlobeNewswire) +5.29%
Jan-04-23 06:30AM
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-01-22 09:55AM
Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet
(Zacks)
Nov-21-22 06:13AM
We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
(Simply Wall St.)
Nov-17-22 04:01PM
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-15-22 09:55AM
How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246%
(Zacks)
Nov-03-22 06:30AM
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
(GlobeNewswire)
Oct-18-22 04:01PM
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-11-22 07:01AM
A Annexon, Inc. (NASDAQ:ANNX) insider increased their holdings by 59% last year
(Simply Wall St.)
Sep-16-22 04:01PM
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-01-22 05:56PM
Amid Huntington's disease hopes and failures, Annexon targets new approach
(American City Business Journals)
Aug-17-22 04:05PM
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Aug-08-22 04:01PM
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
(GlobeNewswire)
Jul-11-22 06:25PM
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
(GlobeNewswire) -13.88%
Jul-08-22 07:00AM
Annexon Announces $130 Million Private Placement Financing
(GlobeNewswire) +14.36%
Jun-07-22 12:19PM
Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues
(Benzinga) +24.92%
06:30AM
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntingtons Disease
(GlobeNewswire)
Jun-02-22 06:30AM
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
(GlobeNewswire)
Jun-01-22 07:30AM
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
(GlobeNewswire) -5.10%
May-09-22 04:01PM
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
(GlobeNewswire)
May-05-22 06:30AM
Annexon Biosciences to Participate in Upcoming May Investor Conferences
(GlobeNewswire)
Apr-21-22 06:02AM
Insider Buying: The Annexon, Inc. (NASDAQ:ANNX) CEO, President & Director Just Bought 59% More Shares
(Simply Wall St.) -5.86%
Apr-18-22 10:35AM
Is Annexon (NASDAQ:ANNX) In A Good Position To Invest In Growth?
(Simply Wall St.)
Apr-07-22 06:30AM
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
(GlobeNewswire) -5.34%
Apr-04-22 06:30AM
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
(GlobeNewswire) +15.41%
Mar-03-22 04:01PM
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntingtons Disease at AAN 2022
(GlobeNewswire)
Mar-01-22 04:01PM
Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire)
Feb-28-22 06:30AM
Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
(GlobeNewswire) -5.54%
Jan-20-22 06:30AM
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors
(GlobeNewswire)
Jan-05-22 05:10PM
Why Annexon Biosciences Stock Plummeted 34% Today
(Motley Fool) -34.06%
06:33AM
Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
(Benzinga)
Jan-04-22 04:05PM
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntingtons Disease Following Six-Month Treatment
(GlobeNewswire) -7.79%
06:30AM
Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-31-21 08:30AM
Do Options Traders Know Something About Annexon (ANNX) Stock We Don't?
(Zacks)
Dec-13-21 09:00AM
Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition
(GlobeNewswire) -6.15%
Nov-30-21 05:24AM
10 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Greens Redmile Group
(Insider Monkey) +15.12%
Nov-28-21 11:17AM
3 Strong Buy Stocks for Bottom-Fishing Investors
(TipRanks)
Nov-09-21 04:01PM
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
(GlobeNewswire)
Oct-19-21 06:38AM
We're Not Very Worried About Annexon's (NASDAQ:ANNX) Cash Burn Rate
(Simply Wall St.)
Oct-04-21 10:49AM
Annexon, Inc. (ANNX): Hedge Fund Sentiment Unchanged
(Insider Monkey)
06:30AM
Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer
(GlobeNewswire)
Sep-23-21 06:30AM
Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
(GlobeNewswire)
Sep-20-21 06:30AM
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
(GlobeNewswire)
Sep-16-21 11:30AM
EVP And Chief Scientific Officer Of Annexon Trades $351.08 Thousand In Company Stock
(Benzinga)
Aug-16-21 04:01PM
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
(GlobeNewswire)
Jul-22-21 07:00AM
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases
(GlobeNewswire)
May-21-21 06:30AM
Moving Average Crossover Alert: Annexon (ANNX)
(Zacks)
May-17-21 04:05PM
Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results
(GlobeNewswire)
May-05-21 07:00AM
Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference
(GlobeNewswire)
Apr-22-21 01:47AM
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
(Simply Wall St.)
Mar-25-21 07:00AM
Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights
(GlobeNewswire)
Mar-01-21 01:11PM
Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy
(Benzinga)
07:00AM
Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy
(GlobeNewswire)
Feb-08-21 07:00AM
Annexon Welcomes William H. Carson, M.D. to the Board of Directors
(GlobeNewswire) +8.18%
Jan-12-21 07:00AM
Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics
(GlobeNewswire)
Jan-05-21 07:00AM
Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference
(GlobeNewswire) -5.52%
Dec-21-20 07:00AM
Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome
(GlobeNewswire) -9.21%
Dec-11-20 01:15PM
Is ANNX A Good Stock To Buy Now?
(Insider Monkey)
Nov-16-20 04:01PM
Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights
(GlobeNewswire)
Nov-12-20 04:05PM
Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntingtons Disease Clinical Program
(GlobeNewswire)
Oct-24-20 10:13AM
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
(Simply Wall St.)
Sep-08-20 04:01PM
Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
(GlobeNewswire)
Jul-30-20 08:00AM
Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer
(GlobeNewswire)
Jul-28-20 04:05PM
Annexon Announces Closing of Initial Public Offering
(GlobeNewswire)
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bain Capital Life Sciences Inv10% OwnerMay 25Buy2.13300,000639,7205,701,926May 30 09:54 PM
Love DouglasPresident & CEOFeb 15Sale5.876,57138,564197,646Feb 17 05:12 PM
Lew JenniferEVP & Chief Financial OfficerFeb 14Sale6.301661,04629,542Feb 15 06:59 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 14Sale6.3014490727,805Feb 15 07:00 PM
Lew JenniferEVP & Chief Financial OfficerFeb 13Sale6.311,74210,98929,708Feb 15 06:59 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 13Sale6.301,5019,46127,949Feb 15 07:00 PM
Satter Muneer ADirectorFeb 10Buy6.802,647,05817,999,9947,056,024Feb 14 04:31 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

XLO

Xilio Therapeutics Inc

Last Close
Dec 01 • 04:00PM ET
1.04
Dollar change
+0.14
Percentage change
15.54 		%
XLO Xilio Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-2.96 Insider Own49.72% Shs Outstand27.43M Perf Week-12.24%
Market Cap28.63M Forward P/E- EPS next Y-2.71 Insider Trans0.00% Shs Float13.84M Perf Month-54.89%
Income-81.22M PEG- EPS next Q-0.73 Inst Own25.23% Short Float / Ratio0.21% / 1.28 Perf Quarter-64.14%
Sales0.00M P/S- EPS this Y11.02% Inst Trans-6.70% Short Interest0.03M Perf Half Y-65.10%
Book/sh1.91 P/B0.55 EPS next Y5.50% ROA-69.04% Target Price9.67 Perf Year-57.02%
Cash/sh2.17 P/C0.48 EPS next 5Y- ROE-90.85% 52W Range0.85 - 4.92 Perf YTD-61.34%
Dividend- P/FCF- EPS past 5Y- ROI-133.33% 52W High-78.86% Beta-0.27
Dividend %- Quick Ratio3.81 Sales past 5Y0.00% Gross Margin- 52W Low22.35% ATR0.22
Employees89 Current Ratio3.81 Sales Q/Q- Oper. Margin0.00% RSI (14)31.65 Volatility14.15% 18.92%
OptionableNo Debt/Eq0.27 EPS Q/Q15.76% Profit Margin- Rel Volume0.99 Prev Close0.90
ShortableYes LT Debt/Eq0.16 EarningsNov 09 AMC Payout- Avg Volume22.64K Price1.04
Recom1.25 SMA20-28.79% SMA50-42.32% SMA200-60.76% Volume22,441 Change15.54%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Nov-09-23 04:01PM
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
(GlobeNewswire) -13.04%
Nov-03-23 12:00PM
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
(GlobeNewswire)
Oct-31-23 09:15AM
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
(GlobeNewswire)
Sep-27-23 05:02PM
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting
(GlobeNewswire)
Sep-05-23 08:30AM
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
(GlobeNewswire)
07:30AM Loading…
07:30AM
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
(GlobeNewswire)
Aug-18-23 04:27AM
Q2 2023 Xilio Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
(GlobeNewswire)
Aug-03-23 04:05PM
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
(GlobeNewswire)
May-25-23 05:01PM
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
(GlobeNewswire)
May-09-23 07:30AM
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
(GlobeNewswire)
Apr-03-23 04:05PM
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-02-23 04:05PM
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire) -7.37%
Feb-27-23 07:30AM
Xilio Therapeutics to Present at Upcoming Investor Conferences
(GlobeNewswire) +5.72%
Feb-16-23 07:30AM
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
(GlobeNewswire)
07:30AM Loading…
Feb-02-23 07:30AM
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
(GlobeNewswire)
Jan-26-23 05:30AM
Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most
(Simply Wall St.)
Jan-25-23 09:45AM
These 2 Strong Buy Penny Stocks Are on Track for Massive Gains, Say Analysts
(TipRanks) +36.92%
Nov-23-22 07:30AM
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
(GlobeNewswire) +7.94%
Nov-09-22 07:30AM
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
(GlobeNewswire)
Nov-04-22 07:30AM
Xilio Therapeutics to Present at Cowen 6th Annual IO Next Summit
(GlobeNewswire)
Sep-22-22 04:05PM
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
(GlobeNewswire)
Sep-15-22 04:05PM
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
(GlobeNewswire) +15.38%
Sep-06-22 04:05PM
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
(GlobeNewswire) +8.21%
Aug-11-22 09:41AM
Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth?
(Simply Wall St.)
Aug-09-22 07:30AM
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
(GlobeNewswire) -26.22%
Jun-16-22 07:30AM
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
(GlobeNewswire)
May-18-22 07:30AM
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
(GlobeNewswire) -9.56%
May-17-22 07:30AM
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
(GlobeNewswire) -5.18%
May-12-22 07:30AM
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
(GlobeNewswire)
06:30AM Loading…
Apr-07-22 06:30AM
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
(GlobeNewswire)
Mar-01-22 06:30AM
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire) -7.56%
Feb-28-22 06:30AM
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
(GlobeNewswire) -10.42%
Feb-07-22 05:38PM
RiverVest Venture Management LLC Buys Xilio Therapeutics Inc
(GuruFocus.com)
Feb-03-22 06:30AM
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
(GlobeNewswire)
Jan-25-22 10:27AM
Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares?
(Simply Wall St.)
Jan-20-22 07:30AM
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
(GlobeNewswire) +9.79%
Jan-06-22 07:30AM
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
(GlobeNewswire)
Dec-02-21 07:30AM
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results
(GlobeNewswire) -12.46%
Nov-12-21 07:00AM
Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
(GlobeNewswire) -6.69%
Oct-27-21 07:45AM
4 Stocks Insiders Are Buying
(Benzinga)
Oct-26-21 04:05PM
Xilio Therapeutics Announces Closing of Initial Public Offering
(GlobeNewswire)
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2023 FINVIZ.com. All Rights Reserved.